Explore detailed financial insights for NSE: Supriya Lifescience Limited, including share price, quarterly results, governance, and stock forecasts for 2025.

NSE: Supriya Lifescience Limited Share Price Today, Share Analysis, Latest Updates & Insights | Fincept

Stay informed with the latest announcements for Supriya, including updates on board meetings and corporate actions.

SUPRIYA
Supriya Lifescience Limited - https://www.supriyalifescience.com
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, anti-malarial products, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, it also offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, the company is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessasion, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic, stem cell transplantation, and anti-migraine. The company was founded in 1987 and is headquartered in Mumbai, India.

Supriya Lifescience Limited Share Price Today

688.80
OPEN
727.05
HIGH
672.00
LOW
715.90
CLOSE
373 K
VOLUME
5,738 Cr
Market Cap
545451
Average Volume
Healthcare
Sector
NSI
Exchange

Supriya Lifescience Limited Share Analysis & 2025 Insights

// -->

Investor Presentations

Date Description Download
SIP
Lumpsum
₹25,000
12%
10 Yr

Invested Amount: ₹

Estimated Returns: ₹

Total Value: ₹

NSE: SUPRIYA Stock Actions

Company
Symbol
ISIN
Subject
Ex Date
Face Value
Broadcast Date
Supriya Lifescience Limited
SUPRIYA
INE07RO01027
Annual General Meeting/Dividend - Rs 0.80 Per Share
20 Sep 2024
2
N/A
Supriya Lifescience Limited
SUPRIYA
INE07RO01027
Annual General Meeting/Dividend - Re 0.60 Per Share
15 Sep 2023
2
N/A
Supriya Lifescience Limited
SUPRIYA
INE07RO01027
Annual General Meeting/Dividend - Re 0.60 Per Share
01 Sep 2022
2
N/A

NSE: SUPRIYA Recent Announcements

Symbol
Date
Description
Industry
SUPRIYA
02 Jan 2025, 15:15:18
Analysts/Institutional Investor Meet/Con. Call Updates
N/A
SUPRIYA
02 Jan 2025, 14:23:04
Analysts/Institutional Investor Meet/Con. Call Updates
N/A
SUPRIYA
02 Jan 2025, 11:47:53
General Updates
N/A
SUPRIYA
01 Jan 2025, 15:41:01
News Verification
N/A
SUPRIYA
01 Jan 2025, 14:11:08
News Verification
N/A

NSE: SUPRIYA Corporate Governance

Name
Symbol
Timestamp
Submission Date
XBRL Document
Supriya Lifescience Limited
SUPRIYA
14 Oct 2024, 14:49:00
14 Oct 2024, 14:49:00
Supriya Lifescience Limited
SUPRIYA
16 Aug 2024, 16:45:00
16 Aug 2024, 16:45:00
Supriya Lifescience Limited
SUPRIYA
17 Apr 2024, 11:43:00
17 Apr 2024, 12:00:00
Supriya Lifescience Limited
SUPRIYA
15 Jan 2024, 14:45:00
15 Jan 2024, 15:15:00
Supriya Lifescience Limited
SUPRIYA
21 Oct 2023, 13:45:00
21 Oct 2023, 14:15:00

NSE: SUPRIYA Detailed Governance

Category
Date of Birth
Date of Initial Appointment
DIN
Director Name
Status
Chairperson & Executive Director
29 Dec 1955
26 Mar 2008
01456982
Satish Waman Wagh
Active
Executive Director
23 May 1958
26 Mar 2008
00833912
Smita Satish Wagh
Active
Executive Director-MD
22 Jun 1990
01 Jul 2019
08491410
Saloni Satish Wagh
Active
Executive Director-MD
27 Sep 1991
01 Jul 2019
08491420
Shivani Satish Wagh
Active
Executive Director
01 Jun 1964
26 May 2023
07743507
Balasaheb Gulabrao Sawant
Active

NSE: SUPRIYA Board Meetings

Purpose
Symbol
Industry
ISIN
Name
Time
SUPRIYA LIFESCIENCE LIMITED has informed the Exchange about Board Meeting to be held on 28-Oct-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2024 .
SUPRIYA
N/A
INE07RO01027
Supriya Lifescience Limited
21 Oct 2024, 11:16:47
Financial Results
SUPRIYA
N/A
INE07RO01027
Supriya Lifescience Limited
03 Aug 2024, 15:08:16
SUPRIYA LIFESCIENCE LIMITED has informed the Exchange about Board Meeting to be held on 28-May-2024 to consider and approve the Yearly Audited Financial results of the Company for the period ended March 2024 and Dividend.
SUPRIYA
N/A
INE07RO01027
Supriya Lifescience Limited
20 May 2024, 15:32:05
Financial Results
SUPRIYA
N/A
INE07RO01027
Supriya Lifescience Limited
30 Jan 2024, 13:23:03
Financial Results
SUPRIYA
N/A
INE07RO01027
Supriya Lifescience Limited
27 Oct 2023, 13:22:02

NSE: SUPRIYA Event Calendar

Purpose
Symbol
Industry
ISIN
Name
Time
Description
Financial Results
SUPRIYA
-
INE07RO01027
Supriya Lifescience Limited
21 Oct 2024, 00:00:00
To consider and approve the financial results for the period ended September 30, 2024
Financial Results
SUPRIYA
-
INE07RO01027
Supriya Lifescience Limited
03 Aug 2024, 00:00:00
To consider and approve the financial results for the period ended Jun 30, 2024
Financial Results/Dividend
SUPRIYA
-
INE07RO01027
Supriya Lifescience Limited
20 May 2024, 00:00:00
To consider and approve the financial results for the period ended March 31, 2024 and dividend
Financial Results
SUPRIYA
-
INE07RO01027
Supriya Lifescience Limited
30 Jan 2024, 00:00:00
To consider and approve the financial results for the period ended December 31, 2023
Financial Results
SUPRIYA
-
INE07RO01027
Supriya Lifescience Limited
27 Oct 2023, 00:00:00
To consider and approve the financial results for the period ended September 30, 2023

NSE: SUPRIYA Balance Sheet Data In (Cr)

date period_type Ordinary Shares Number Share Issued Net Debt Total Debt Tangible Book Value Invested Capital Working Capital Net Tangible Assets Capital Lease Obligations Common Stock Equity Total Capitalization Total Equity Gross Minority Interest Stockholders Equity Other Equity Interest Retained Earnings Additional Paid In Capital Capital Stock Common Stock Total Liabilities Net Minority Interest Total Non Current Liabilities Net Minority Interest Other Non Current Liabilities Non Current Pension And Other Postretirement Benefit Plans Non Current Deferred Revenue Non Current Deferred Taxes Liabilities Long Term Debt And Capital Lease Obligation Long Term Capital Lease Obligation Long Term Debt Long Term Provisions Current Liabilities Other Current Liabilities Current Deferred Taxes Liabilities Current Debt And Capital Lease Obligation Current Capital Lease Obligation Current Debt Pensionand Other Post Retirement Benefit Plans Current Current Provisions Payables Other Payable Dividends Payable Total Tax Payable Accounts Payable Total Assets Total Non Current Assets Other Non Current Assets Non Current Prepaid Assets Investmentin Financial Assets Available For Sale Securities Goodwill And Other Intangible Assets Other Intangible Assets Net PPE Accumulated Depreciation Gross PPE Construction In Progress Other Properties Machinery Furniture Equipment Buildings And Improvements Land And Improvements Properties Current Assets Other Current Assets Current Deferred Assets Restricted Cash Prepaid Assets Inventory Other Inventories Finished Goods Work In Process Raw Materials Other Receivables Taxes Receivable Accounts Receivable Allowance For Doubtful Accounts Receivable Gross Accounts Receivable Cash Cash Equivalents And Short Term Investments Other Short Term Investments Cash And Cash Equivalents Cash Equivalents Cash Financial
2024-09-30T00:00:00 quarterly 80,482,800.00 80,482,800.00 0.00 55,090,000.00 9,031,910,000.00 9,058,880,000.00 3,379,220,000.00 9,031,910,000.00 55,090,000.00 9,058,880,000.00 9,058,880,000.00 9,058,880,000.00 9,058,880,000.00 8,897,910,000.00 0.00 0.00 160,970,000.00 160,970,000.00 1,065,030,000.00 310,630,000.00 0.00 0.00 0.00 240,850,000.00 52,180,000.00 52,180,000.00 0.00 17,600,000.00 754,400,000.00 95,850,000.00 0.00 2,910,000.00 2,910,000.00 0.00 0.00 3,800,000.00 624,070,000.00 0.00 0.00 0.00 624,070,000.00 10,123,910,000.00 5,990,290,000.00 11,660,000.00 0.00 724,880,000.00 0.00 26,970,000.00 0.00 5,226,780,000.00 0.00 5,226,780,000.00 2,175,290,000.00 3,051,490,000.00 0.00 0.00 0.00 0.00 4,133,620,000.00 1,119,220,000.00 0.00 0.00 0.00 1,079,850,000.00 0.00 0.00 0.00 0.00 7,680,000.00 0.00 1,057,260,000.00 0.00 0.00 869,610,000.00 94,560,000.00 775,050,000.00 0.00 0.00
2024-03-31T00:00:00 quarterly 80,482,800.00 80,482,800.00 0.00 54,880,000.00 8,137,110,000.00 8,153,660,000.00 3,209,100,000.00 8,137,110,000.00 54,880,000.00 8,153,660,000.00 8,153,660,000.00 8,153,673,000.00 8,153,660,000.00 7,992,700,000.00 6,004,470,000.00 1,985,400,000.00 160,970,000.00 160,970,000.00 1,058,707,000.00 289,767,000.00 7,000.00 8,040,000.00 0.00 231,520,000.00 50,200,000.00 50,200,000.00 0.00 8,040,000.00 768,940,000.00 27,300,000.00 -26,800,000.00 4,680,000.00 4,680,000.00 0.00 3,650,000.00 3,650,000.00 605,690,000.00 10,000,000.00 0.00 0.00 595,690,000.00 9,212,380,000.00 5,234,330,000.00 10,000.00 6,810,000.00 610,820,000.00 610,820,000.00 16,550,000.00 16,550,000.00 4,573,010,000.00 -587,310,000.00 5,160,320,000.00 1,488,250,000.00 488,250,000.00 2,221,970,000.00 857,690,000.00 104,160,000.00 0.00 3,978,040,000.00 1,207,220,000.00 6,880,000.00 22,190,000.00 1,200,340,000.00 852,490,000.00 490,000.00 215,360,000.00 39,100,000.00 597,540,000.00 51,940,000.00 0.00 1,116,830,000.00 -7,450,000.00 1,124,280,000.00 727,370,000.00 45,690,000.00 681,680,000.00 565,340,000.00 116,340,000.00
2024-03-31T00:00:00 annual 80,482,800.00 80,482,800.00 0.00 54,880,000.00 8,137,110,000.00 8,153,660,000.00 3,209,100,000.00 8,137,110,000.00 54,880,000.00 8,153,660,000.00 8,153,660,000.00 8,153,673,000.00 8,153,660,000.00 7,992,700,000.00 6,004,470,000.00 1,985,400,000.00 160,970,000.00 160,970,000.00 1,058,707,000.00 289,767,000.00 7,000.00 8,040,000.00 0.00 231,520,000.00 50,200,000.00 50,200,000.00 0.00 8,040,000.00 768,940,000.00 27,300,000.00 -26,800,000.00 4,680,000.00 4,680,000.00 0.00 3,650,000.00 3,650,000.00 605,690,000.00 10,000,000.00 0.00 0.00 595,690,000.00 9,212,380,000.00 5,234,330,000.00 10,000.00 6,810,000.00 610,820,000.00 610,820,000.00 16,550,000.00 16,550,000.00 4,573,010,000.00 -587,310,000.00 5,160,320,000.00 1,488,250,000.00 488,250,000.00 2,221,970,000.00 857,690,000.00 104,160,000.00 0.00 3,978,040,000.00 1,207,220,000.00 6,880,000.00 22,190,000.00 1,200,340,000.00 852,490,000.00 490,000.00 215,360,000.00 39,100,000.00 597,540,000.00 51,940,000.00 0.00 1,116,830,000.00 -7,450,000.00 1,124,280,000.00 727,370,000.00 45,690,000.00 681,680,000.00 565,340,000.00 116,340,000.00
2023-09-30T00:00:00 quarterly 80,482,800.00 80,482,800.00 0.00 57,710,000.00 7,519,070,000.00 7,532,740,000.00 3,452,790,000.00 7,519,070,000.00 56,700,000.00 7,531,730,000.00 7,531,730,000.00 7,531,730,000.00 7,531,730,000.00 7,370,760,000.00 0.00 0.00 160,970,000.00 160,970,000.00 898,570,000.00 242,720,000.00 0.00 0.00 0.00 151,950,000.00 52,610,000.00 52,610,000.00 0.00 38,160,000.00 655,850,000.00 69,330,000.00 0.00 5,100,000.00 4,090,000.00 1,010,000.00 0.00 8,370,000.00 551,970,000.00 0.00 0.00 0.00 551,970,000.00 8,430,300,000.00 4,321,660,000.00 9,360,000.00 0.00 569,530,000.00 569,530,000.00 12,660,000.00 0.00 3,730,110,000.00 0.00 3,730,110,000.00 1,164,580,000.00 2,565,530,000.00 0.00 0.00 0.00 0.00 4,108,640,000.00 1,063,600,000.00 0.00 0.00 0.00 988,250,000.00 0.00 0.00 0.00 0.00 5,560,000.00 0.00 848,350,000.00 0.00 0.00 1,202,880,000.00 162,470,000.00 1,040,410,000.00 0.00 0.00
2023-03-31T00:00:00 quarterly 80,482,800.00 80,482,800.00 0.00 224,680,000.00 6,984,380,000.00 7,160,830,000.00 3,691,070,000.00 6,984,380,000.00 58,430,000.00 6,994,580,000.00 6,994,580,000.00 6,994,584,000.00 6,994,580,000.00 6,833,620,000.00 4,861,620,000.00 1,985,400,000.00 160,970,000.00 160,970,000.00 1,208,186,000.00 250,386,000.00 -4,000.00 58,750,000.00 0.00 136,750,000.00 54,890,000.00 54,890,000.00 0.00 58,750,000.00 957,800,000.00 28,190,000.00 45,870,000.00 169,790,000.00 3,540,000.00 166,250,000.00 8,370,000.00 0.00 650,490,000.00 8,210,000.00 0.00 0.00 642,280,000.00 8,202,770,000.00 3,553,900,000.00 880,000.00 9,280,000.00 250,870,000.00 250,870,000.00 10,200,000.00 10,200,000.00 3,280,580,000.00 -432,930,000.00 3,713,510,000.00 676,280,000.00 453,370,000.00 1,768,060,000.00 724,160,000.00 91,640,000.00 0.00 4,648,870,000.00 -20,000.00 0.00 31,330,000.00 999,160,000.00 1,157,710,000.00 0.00 257,710,000.00 299,860,000.00 600,140,000.00 69,550,000.00 0.00 846,640,000.00 -10,620,000.00 857,260,000.00 1,544,500,000.00 691,980,000.00 852,520,000.00 774,300,000.00 78,220,000.00
2023-03-31T00:00:00 annual 80,482,800.00 80,482,800.00 0.00 224,680,000.00 6,984,380,000.00 7,160,830,000.00 3,691,070,000.00 6,984,380,000.00 58,430,000.00 6,994,580,000.00 6,994,580,000.00 6,994,584,000.00 6,994,580,000.00 6,833,620,000.00 4,861,620,000.00 1,985,400,000.00 160,970,000.00 160,970,000.00 1,208,186,000.00 250,386,000.00 -4,000.00 58,750,000.00 0.00 136,750,000.00 54,890,000.00 54,890,000.00 0.00 58,750,000.00 957,800,000.00 28,190,000.00 45,870,000.00 169,790,000.00 3,540,000.00 166,250,000.00 8,370,000.00 0.00 650,490,000.00 8,210,000.00 0.00 0.00 642,280,000.00 8,202,770,000.00 3,553,900,000.00 880,000.00 9,280,000.00 250,870,000.00 250,870,000.00 10,200,000.00 10,200,000.00 3,280,580,000.00 -432,930,000.00 3,713,510,000.00 676,280,000.00 453,370,000.00 1,768,060,000.00 724,160,000.00 91,640,000.00 0.00 4,648,870,000.00 -20,000.00 0.00 31,330,000.00 999,160,000.00 1,157,710,000.00 0.00 257,710,000.00 299,860,000.00 600,140,000.00 69,550,000.00 0.00 846,640,000.00 -10,620,000.00 857,260,000.00 1,544,500,000.00 691,980,000.00 852,520,000.00 774,300,000.00 78,220,000.00
2022-03-31T00:00:00 annual 80,482,800.00 80,482,800.00 0.00 274,150,000.00 6,141,800,000.00 6,369,830,000.00 3,978,450,000.00 6,141,800,000.00 61,200,000.00 6,156,880,000.00 6,156,880,000.00 6,156,870,000.00 6,156,880,000.00 5,995,910,000.00 4,011,340,000.00 1,985,400,000.00 160,970,000.00 160,970,000.00 1,190,750,000.00 193,760,000.00 10,000.00 29,310,000.00 0.00 111,490,000.00 52,950,000.00 52,950,000.00 0.00 29,310,000.00 996,990,000.00 31,590,000.00 64,110,000.00 221,200,000.00 8,250,000.00 212,950,000.00 4,120,000.00 0.00 497,660,000.00 7,940,000.00 0.00 0.00 489,720,000.00 7,347,620,000.00 2,372,180,000.00 -10,000.00 39,840,000.00 530,000.00 530,000.00 15,080,000.00 15,080,000.00 2,316,740,000.00 -318,970,000.00 2,635,710,000.00 434,090,000.00 252,210,000.00 1,311,050,000.00 546,760,000.00 91,600,000.00 0.00 4,975,440,000.00 30,000.00 0.00 29,770,000.00 381,640,000.00 923,110,000.00 0.00 179,480,000.00 313,030,000.00 430,600,000.00 239,760,000.00 0.00 1,151,830,000.00 -14,050,000.00 1,165,880,000.00 2,249,300,000.00 591,550,000.00 1,657,750,000.00 1,426,160,000.00 231,590,000.00
2021-03-31T00:00:00 annual 25,547,445.00 25,547,445.00 266,300,000.00 721,940,000.00 2,669,720,000.00 3,387,130,000.00 1,194,440,000.00 2,669,720,000.00 20,650,000.00 2,685,840,000.00 2,685,840,000.00 2,685,830,000.00 2,685,840,000.00 0.00 2,537,150,000.00 0.00 146,370,000.00 146,370,000.00 1,768,830,000.00 308,640,000.00 10,000.00 13,010,000.00 0.00 80,110,000.00 20,650,000.00 20,650,000.00 0.00 0.00 1,460,190,000.00 72,550,000.00 152,000,000.00 701,290,000.00 0.00 701,290,000.00 9,060,000.00 0.00 515,880,000.00 5,660,000.00 0.00 151,850,000.00 510,220,000.00 4,454,660,000.00 1,800,030,000.00 10,000.00 11,250,000.00 530,000.00 530,000.00 16,120,000.00 16,120,000.00 1,772,120,000.00 -221,700,000.00 1,993,820,000.00 787,880,000.00 146,520,000.00 698,580,000.00 282,980,000.00 77,860,000.00 0.00 2,654,630,000.00 0.00 0.00 28,510,000.00 95,420,000.00 724,800,000.00 0.00 224,240,000.00 238,010,000.00 262,550,000.00 206,630,000.00 0.00 735,000,000.00 -10,390,000.00 745,390,000.00 864,270,000.00 429,280,000.00 434,990,000.00 426,230,000.00 8,760,000.00
2020-03-31T00:00:00 annual 0.00 0.00 806,670,000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 36,840,000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 21,560,000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -10,000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 15,320,000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

NSE: SUPRIYA Cash Flow Data In (Cr)

date period_type Free Cash Flow Issuance Of Capital Stock Capital Expenditure End Cash Position Other Cash Adjustment Outside Changein Cash Beginning Cash Position Changes In Cash Financing Cash Flow Net Other Financing Charges Interest Paid Cff Cash Dividends Paid Net Common Stock Issuance Common Stock Issuance Net Issuance Payments Of Debt Net Short Term Debt Issuance Net Long Term Debt Issuance Investing Cash Flow Net Other Investing Changes Interest Received Cfi Dividends Received Cfi Net Investment Purchase And Sale Net PPE Purchase And Sale Sale Of PPE Purchase Of PPE Operating Cash Flow Taxes Refund Paid Interest Paid Cfo Change In Working Capital Change In Other Current Liabilities Change In Other Current Assets Change In Payable Change In Inventory Change In Receivables Other Non Cash Items Provisionand Write Offof Assets Depreciation And Amortization Depreciation Pension And Employee Benefit Expense Gain Loss On Investment Securities Gain Loss On Sale Of PPE Net Income From Continuing Operations
2024-03-31T00:00:00 annual -323,480,000.00 0.00 -1,456,550,000.00 749,560,000.00 10,000.00 1,575,820,000.00 -826,270,000.00 -223,590,000.00 0.00 -5,510,000.00 -48,290,000.00 0.00 0.00 -166,250,000.00 -166,250,000.00 0.00 -1,735,750,000.00 0.00 105,750,000.00 50,000.00 -385,000,000.00 -1,456,550,000.00 0.00 -1,456,550,000.00 1,133,070,000.00 -376,450,000.00 0.00 -171,420,000.00 27,550,000.00 -186,040,000.00 -46,590,000.00 305,210,000.00 -271,550,000.00 -100,290,000.00 0.00 158,110,000.00 158,110,000.00 -33,730,000.00 -50,000.00 0.00 1,656,900,000.00
2023-03-31T00:00:00 annual -443,050,000.00 0.00 -1,079,100,000.00 1,575,820,000.00 -10,000.00 2,279,080,000.00 -703,250,000.00 -102,760,000.00 94,930,000.00 -4,990,000.00 -48,290,000.00 0.00 0.00 -46,700,000.00 -46,700,000.00 0.00 -1,236,540,000.00 -10,000.00 94,940,000.00 50,000.00 -252,430,000.00 -1,079,100,000.00 5,430,000.00 -1,079,100,000.00 636,050,000.00 -306,800,000.00 0.00 -338,150,000.00 -144,580,000.00 -417,000,000.00 152,560,000.00 -234,580,000.00 305,450,000.00 -89,950,000.00 0.00 118,150,000.00 118,150,000.00 16,880,000.00 -50,000.00 1,110,000.00 1,234,870,000.00
2022-03-31T00:00:00 annual -111,030,000.00 2,000,000,000.00 -599,040,000.00 2,279,080,000.00 0.00 892,770,000.00 1,386,310,000.00 1,496,520,000.00 70,710,000.00 -36,580,000.00 -43,910,000.00 2,000,000,000.00 2,000,000,000.00 -486,070,000.00 -486,070,000.00 0.00 -598,220,000.00 0.00 0.00 0.00 0.00 -598,220,000.00 820,000.00 -599,040,000.00 488,010,000.00 -609,620,000.00 -3,360,000.00 -1,043,530,000.00 -67,070,000.00 -317,420,000.00 -20,500,000.00 -198,320,000.00 -447,360,000.00 -32,470,000.00 0.00 101,180,000.00 101,180,000.00 0.00 0.00 0.00 2,072,450,000.00
2021-03-31T00:00:00 annual 276,480,000.00 0.00 -482,410,000.00 892,770,000.00 -10,000.00 747,050,000.00 145,720,000.00 -145,160,000.00 49,800,000.00 -38,740,000.00 -39,560,000.00 0.00 0.00 -116,660,000.00 -92,730,000.00 -23,930,000.00 -468,010,000.00 10,000.00 0.00 0.00 0.00 -468,010,000.00 14,400,000.00 -482,410,000.00 758,890,000.00 -299,940,000.00 -4,500,000.00 -668,170,000.00 -138,590,000.00 -66,470,000.00 16,530,000.00 -230,220,000.00 -250,310,000.00 -13,720,000.00 0.00 67,610,000.00 67,610,000.00 0.00 0.00 0.00 1,673,090,000.00
2020-03-31T00:00:00 annual 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 21,730,000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1,480,000.00 0.00 0.00 0.00

NSE: SUPRIYA Income Statement Data In (Cr)

date period_type Tax Effect Of Unusual Items Tax Rate For Calcs Normalized EBITDA Total Unusual Items Total Unusual Items Excluding Goodwill Net Income From Continuing Operation Net Minority Interest Reconciled Depreciation Reconciled Cost Of Revenue EBITDA EBIT Net Interest Income Interest Expense Interest Income Normalized Income Net Income From Continuing And Discontinued Operation Total Expenses Diluted Average Shares Basic Average Shares Diluted EPS Basic EPS Diluted NI Availto Com Stockholders Net Income Common Stockholders Otherunder Preferred Stock Dividend Net Income Net Income Including Noncontrolling Interests Net Income Discontinuous Operations Net Income Continuous Operations Tax Provision Pretax Income Other Non Operating Income Expenses Special Income Charges Other Special Charges Net Non Operating Interest Income Expense Total Other Finance Cost Interest Expense Non Operating Interest Income Non Operating Operating Income Operating Expense Other Operating Expenses Depreciation And Amortization In Income Statement Amortization Depreciation Income Statement Selling General And Administration Selling And Marketing Expense General And Administrative Expense Gross Profit Cost Of Revenue Total Revenue Operating Revenue
2024-03-31T00:00:00 annual -0.09 0.00 185.55 -0.34 -0.34 119.11 15.81 277.19 185.20 169.39 3.21 3.70 8.36 119.36 119.11 399.69 8.05 8.05 0.00 0.00 119.11 119.11 0.00 119.11 119.11 0.00 119.11 46.58 165.69 0.00 -2.58 2.58 3.21 1.45 3.70 8.36 157.75 122.50 0.46 15.81 0.00 15.81 46.37 23.18 23.19 280.25 277.19 557.44 557.44
2023-03-31T00:00:00 annual -0.77 0.00 139.78 -2.80 -2.80 89.86 11.82 230.55 136.98 125.17 6.43 1.68 9.56 91.88 89.86 335.70 8.05 8.05 0.00 0.00 89.86 89.86 0.00 89.86 89.86 0.00 89.86 33.63 123.49 9.49 -2.80 2.80 6.43 1.45 1.68 9.56 115.32 105.14 0.61 11.82 0.00 11.82 43.09 23.87 19.23 220.46 230.55 451.02 451.02
2022-03-31T00:00:00 annual -0.10 0.00 220.54 -0.37 -0.37 151.81 10.12 229.89 220.17 210.06 3.22 2.81 7.42 152.08 151.81 317.22 8.05 8.05 0.00 0.00 151.81 151.81 0.00 151.81 151.81 0.00 151.81 55.44 207.25 0.01 -0.37 0.37 3.22 1.39 2.81 7.42 202.16 87.33 0.33 10.12 0.39 10.12 36.11 22.38 13.73 289.49 229.89 519.37 519.37
2021-03-31T00:00:00 annual 0.00 0.00 177.06 0.00 0.00 123.59 6.76 151.17 177.06 170.23 0.91 2.92 4.99 123.59 123.59 220.92 2.55 2.55 0.00 0.00 123.59 123.59 0.00 123.59 123.59 0.00 123.59 43.72 167.31 0.02 0.00 -0.03 0.91 1.16 2.92 4.99 164.44 69.76 0.50 6.84 0.39 6.44 33.64 23.12 10.52 234.20 151.17 385.37 385.37

FII & DII Data (In Cr)

Date FII Gross Purchase FII Gross Sales FII Net Purchase / Sales DII Gross Purchase DII Gross Sales DII Net Purchase / Sales
2025-02-03 12,505.92 16,464.29 -3,958.37 19,319.48 16,611.25 2,708.23
2025-01-30 10,513.63 15,096.58 -4,582.95 13,934.35 11,768.46 2,165.89
2025-01-29 7,644.40 10,230.83 -2,586.43 12,871.38 11,078.67 1,792.71
2025-01-27 9,488.57 14,504.03 -5,015.46 16,503.43 9,861.28 6,642.15
2025-01-24 11,230.47 13,988.96 -2,758.49 12,835.41 10,433.10 2,402.31
2025-01-23 13,316.55 18,779.07 -5,462.52 14,412.73 10,700.18 3,712.55
2025-01-22 12,936.64 16,962.89 -4,026.25 15,437.18 11,796.96 3,640.22
Quarterly Results
Profit & Loss
Piotroski F-Score
5/9
0 1 2 3 4 5 6 7 8 9

Key Metrics

EPS

19.56

P/E

36.451942

P/B

6.3612437

Dividend Yield

0.11%

Market Cap

5,738.42 Cr.

Face Value

112.085

Book Value

112.085

ROE

25.2%

EBITDA Growth

527.34 Cr.

Debt/Equity

0.608

Short Term

Subscribe to unlock this feature

Medium Term

Subscribe to unlock this feature

Long Term

Subscribe to unlock this feature

Yearly Stock Performance Heatmap

Latest Updates

SUPRIYA News

Ashoka Buildcon Arm Signs Rs 1,391 Crore Pact With NHAI

Ashoka Buildcon Ltd. announced on Monday, via an exchange filing, that its wholly owned subsidiary, Ashoka Bowaichandi Guskara Road Pvt Ltd., has exec...

Source: www.ndtvprofit.com
Date: 06 Jan 2025, 19:50

SUPRIYA News

Budget 2025: Rahul Bajoria On Addressing Income Growth And Consumption Trends

"However, discretionary, high-value consumption is taking a step back due to income growth settling at high single digits." Over the past fe...

Source: www.ndtvprofit.com
Date: 06 Jan 2025, 19:47

SUPRIYA News

FPIs Stay Net Sellers, Sell Stocks Worth Rs 2,575 Crore

Foreign portfolio investors stayed net sellers for the second straight session on Monday and sold stocks worth approximately Rs 2,575.1 crore, accordi...

Source: www.ndtvprofit.com
Date: 06 Jan 2025, 19:37

SUPRIYA News

Budget 2025: AMFI Seeks Tax Policy Reforms To Drive Mutual Fund Investments In 15-Point Proposal

The Association of Mutual Funds of India on Monday released a 15-point proposal for Union Budget 2025-26 requesting changes in tax policies that are i...

Source: www.ndtvprofit.com
Date: 06 Jan 2025, 19:23

SUPRIYA News

Apple iPhone SE 4: Price To Features, 11 Things You Need To Know

iPhone 16e (Not iPhone SE 4): If recent reports are to be believed, Apple may discontinue the SE label and rename iPhone SE 4 as iPhone 16e. Most Affo...

Source: www.ndtvprofit.com
Date: 06 Jan 2025, 19:12

SUPRIYA News

Rupee Closed Weaker Against The US Dollar

The rupee weakened by five paise to close at 85.83 against the US dollar. The Indian rupee had declined to a fresh low against the US dollar during th...

Source: www.ndtvprofit.com
Date: 06 Jan 2025, 15:54

SUPRIYA News

Table Space Founder Amit Banerji Dies Of Heart Attack At Age Of 45

Amit Banerji, the founder, chairman and chief executive officer of managed workspace provider Table Space, died after suffering from a heart attack, r...

Source: www.ndtvprofit.com
Date: 06 Jan 2025, 19:09

SUPRIYA News

War Fatigue, Economic Breakdown Or Pro-West? Why Syria's Al-Sharaa Is Seen Soft On Israel

The strategic positions have been used by Israeli forces to carry out hundreds of strikes to destroy Syria's military infrastructure. In 2011, be...

Source: www.ndtvprofit.com
Date: 06 Jan 2025, 19:00

Popular Questions

How to Buy supriya Shares on Fincept?

You can buy Supriya Lifescience Limited shares on Different Brokers & Banks by creating an account and completing KYC verification online.

What is the Market Cap of supriya?

The market capitalization of Supriya Lifescience Limited is ₹5,738 Cr as of 05 Feb 2025.

What are the PE and PB ratios of Supriya Lifescience Limited?

The PE and PB ratios of Supriya Lifescience Limited are Not Available and 6.3612437 respectively as of 05 Feb 2025.

What is the 52 Week High of Supriya Lifescience Limited?

The 52-week high of Supriya Lifescience Limited is ₹835.2 as of 05 Feb 2025.

What is the 52 Week Low of Supriya Lifescience Limited?

The 52-week low of Supriya Lifescience Limited is ₹288.9 as of 05 Feb 2025.

What are the earnings per share (EPS) for Supriya Lifescience Limited?

The Earnings Per Share (EPS) of Supriya Lifescience Limited is ₹19.56 as per the most recent quarterly results available on Fincept.

What is the ROE (Return on Equity) of Supriya Lifescience Limited?

The Return on Equity (ROE) of Supriya Lifescience Limited is 25.2% as per the most recent financial year data. Explore more on Fincept.

GENSOL

View Stock

TIIL

View Stock

SEPC-RE2

View Stock

MADHUCON

View Stock

DISHTV

View Stock

EMBDL

View Stock

HGINFRA

View Stock

SUMIT

View Stock

OBEROIRLTY

View Stock

TPLPLASTEH

View Stock

SURANASOL

View Stock

BLUEJET

View Stock

PREMEXPLN

View Stock